EP4716552A1 - Verwendung von amivantamab zur behandlung von kopf-hals-krebs - Google Patents

Verwendung von amivantamab zur behandlung von kopf-hals-krebs

Info

Publication number
EP4716552A1
EP4716552A1 EP25703666.5A EP25703666A EP4716552A1 EP 4716552 A1 EP4716552 A1 EP 4716552A1 EP 25703666 A EP25703666 A EP 25703666A EP 4716552 A1 EP4716552 A1 EP 4716552A1
Authority
EP
European Patent Office
Prior art keywords
antibody
subject
administered
seq
cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP25703666.5A
Other languages
English (en)
French (fr)
Inventor
Joshua BAUML
Roland Knoblauch
Mahadi BAIG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of EP4716552A1 publication Critical patent/EP4716552A1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP25703666.5A 2024-01-22 2025-01-21 Verwendung von amivantamab zur behandlung von kopf-hals-krebs Pending EP4716552A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202463623555P 2024-01-22 2024-01-22
US202463720828P 2024-11-15 2024-11-15
PCT/IB2025/050613 WO2025158277A1 (en) 2024-01-22 2025-01-21 Use of amivantamab to treat head and neck cancer

Publications (1)

Publication Number Publication Date
EP4716552A1 true EP4716552A1 (de) 2026-04-01

Family

ID=94480948

Family Applications (1)

Application Number Title Priority Date Filing Date
EP25703666.5A Pending EP4716552A1 (de) 2024-01-22 2025-01-21 Verwendung von amivantamab zur behandlung von kopf-hals-krebs

Country Status (3)

Country Link
EP (1) EP4716552A1 (de)
TW (1) TW202547868A (de)
WO (1) WO2025158277A1 (de)

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US7767429B2 (en) 2003-03-05 2010-08-03 Halozyme, Inc. Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
CA2577082A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20090155275A1 (en) 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EA036569B1 (ru) 2008-12-09 2020-11-24 Галозим, Инк. Способ получения полипептида гиалуронидазы ph20
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
PL2773671T3 (pl) 2011-11-04 2022-01-24 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerycznego z mutacjami w domenie fc
WO2013102144A2 (en) 2011-12-30 2013-07-04 Halozyme, Inc. Ph20 polypeptede variants, formulations and uses thereof
ES2831374T3 (es) 2012-11-21 2021-06-08 Janssen Biotech Inc Anticuerpos de EGFR/c-Met biespecíficos
US12528869B2 (en) * 2020-08-25 2026-01-20 Janssen Biotech, Inc. Treatment of non-small cell lung cancer with EGFR mutations
TW202308689A (zh) 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物

Also Published As

Publication number Publication date
TW202547868A (zh) 2025-12-16
WO2025158277A1 (en) 2025-07-31

Similar Documents

Publication Publication Date Title
US11771762B2 (en) Anti-ErbB3 antibodies and uses thereof
JP7573062B2 (ja) がん治療における化学療法剤と組み合わせた抗ｆｇｆｒ２抗体
TWI796746B (zh) 用於治療輕鏈型類澱粉變性症及其他cd38-陽性血液惡性疾病之抗-cd38抗體
JP6654165B2 (ja) 抗ｔｉｅ２抗体およびその使用
US11655303B2 (en) Anti-CD39 antibody compositions and methods
TW201402610A (zh) 抗－ｅｇｆｒ抗體及其用途
US20250257139A1 (en) Use of Amivantamab to Treat Colorectal Cancer
TW202327650A (zh) 治療多發性骨髓瘤之方法
KR20260013482A (ko) 비-소세포 폐암(nsclc)의 치료 방법
US20230250195A1 (en) Methods for Reducing Infusion-Related Reactions in Patients Treated with EGFR/Met Bispecific Antibodies
WO2025158277A1 (en) Use of amivantamab to treat head and neck cancer
KR20240099411A (ko) 항-cd38 항체를 사용한 치료에서 코르티코스테로이드 감소
KR20230156094A (ko) Egfr-활성화 돌연변이가 결여된 암의 치료
WO2025191459A1 (en) Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
JP2023523006A (ja) Ｌｇｒ５及びｅｇｆｒに結合する抗体によるがんの治療
US20240317866A1 (en) Use of Anti-EGFR/Anti-Met Antibody to Treat Gastric or Esophageal Cancer
US20240067736A1 (en) Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer
TW202612730A (zh) Ｅｇｆｒ結合和／或補體活化抗體的給藥方案
WO2025244529A1 (en) Dosing regimen of an egfr binding and/or complement activating antibody
KR20260066109A (ko) 비소세포 폐암을 치료하는 방법
KR20250158056A (ko) 이중특이성 항-egfr/c-met 항체 및 항-pd-1 항체를 사용한 병용 요법
HK40108897A (zh) 埃万妥单抗用於治疗结肠直肠癌的用途
AU2022355201A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
HK40128024A (zh) 双特异性抗egfr/c-met抗体和抗pd-1抗体的组合疗法
HK40104478A (zh) 用於鉴定进行组合治疗的癌症患者的方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20260401